Princess Margaret Hospital
Personalized Residual Disease Assays Show Promise to Overcome Liquid Biopsy Challenges in Sarcomas
Premium
New data presented at the ASCO annual meeting this week showed that tumor-informed assays could detect emerging recurrence ahead of imaging.
Princess Margaret Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
Inivata's InVisionFirst-Lung and RaDaR assays will support studies of the use of liquid biopsies in early and minimal residual disease detection.
Liquid Biopsy Startup Adela Launches With $60M Series A Financing Round
The Toronto-based company will use the funding to commercialize its cell-free DNA methylation sequencing technology as an early cancer detection test.
Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium
Epic Sciences will donate its No Cell Left Behind platform to the clinical trial, which will enroll about 1,000 patients over three years.
Few Cancer Patients With Tumor Profiles Enter Genotype-Matched Trials, But Response Rate is Higher
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.